Insider · CIK 0001952986
Howard Berman
Files at AVIR (Atea Pharmaceuticals, Inc.), COYA (Coya Therapeutics, Inc.). First filing -, latest -.
Howard Berman files SEC Form 4 as director and chair at AVIR (Atea Pharmaceuticals, Inc.), and also at COYA (Coya Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Howard Berman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +26,700 | $0.00 | $0 | 26,700 | Jun 23, 2026 |
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,700 | $0.00 | $0 | 37,700 | Jun 23, 2026 |
| Jan 22, 2026 | COYA Coya Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +15,257 | $0.00 | $0 | 15,257 | Jan 26, 2026 |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +164,800 | $0.00 | $0 | 164,800 | Jun 24, 2025 |
| Jan 9, 2025 | COYA Coya Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +150,602 | $0.00 | $0 | 150,602 | Jan 13, 2025 |
Questions about Howard Berman
Answered from the filings on this page, as of the latest one.
Is Howard Berman buying or selling?
Howard Berman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Howard Berman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Howard Berman has 0.
Where does Howard Berman file Form 4?
Howard Berman has filed Form 4 at AVIR (Atea Pharmaceuticals, Inc.); COYA (Coya Therapeutics, Inc.) as Executive Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.